Lyell Immunopharma, Inc.LYELNASDAQ

Revenue (LTM)

$36000

-41.0% YoY

Net Income (LTM)

$-274M

+20.0% YoY

Free Cash Flow

$-151M

Revenue CAGR (5Y)

-65.9%

Marginsdeclining

FCF($0.2B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	11	85↑695.1%	0↓99.8%	0↓53.1%	0↓41.0%
Gross Profit	11	85↑695.1%	0↓99.8%	0↓53.1%	-12↓18957.4%
Operating Income	-215	-187↑12.9%	-247↓32.0%	-359↓45.2%	-204↑43.2%
Net Income	-250	-183↑26.8%	-235↓28.1%	-343↓46.2%	-274↑20.0%
EBITDA	-201	-169↑16.0%	-227↓34.1%	-201↑11.5%	-192↑4.2%
EPS Diluted	-1.03	-0.74↑28.1%	-0.93↓26.1%	-1.31↓40.1%	-16.06↓1126.0%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	294	124↓58.0%	146↑17.9%	106↓27.5%	60↓43.0%
Total Current Assets	626	651↑4.0%	555↓14.8%	380↓31.6%	261↓31.3%
Total Assets	1,127	938↓16.8%	750↓20.0%	491↓34.6%	340↓30.7%
Total Current Liabilities	47	37↓20.8%	35↓6.8%	54↑55.8%	49↓8.1%
Total Liabilities	198	104↓47.2%	95↓8.9%	108↑13.6%	92↓15.0%
Total Equity	930	833↓10.4%	655↓21.4%	383↓41.5%	248↓35.2%
Total Debt	68	68↓0.2%	63↓6.7%	59↓6.6%	42↓28.9%
Net Debt	-226	-56↑75.3%	-82↓47.7%	-47↑43.5%	-18↑60.8%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-126	-170↓34.3%	-164↑3.5%	-162↑0.8%	-150↑7.6%
Capital Expenditure	-66	-24↑62.9%	-3↑88.9%	-0↑82.7%	-1↓68.1%
Free Cash Flow	-192	-194↓1.1%	-166↑14.2%	-163↑2.1%	-151↑7.4%
Stock-Based Comp	62	0	47	33↓29.6%	42↑26.2%
Net Change in Cash	153	-170↓211.0%	22↑113.0%	-39↓274.9%	-46↓17.8%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance